BofA analyst Tazeen Ahmad raised the firm’s price target on Taysha Gene Therapies (TSHA) to $9 from $8 and keeps a Buy rating on the shares after the company presented supplemental analysis from the REVEAL Part A study at the CNS Annual Meeting. The firm notes that it currently assigns TSHA-102 60% odds of success and 40% market share for peak risk-adjusted sales of $1.3B in 2031 following a 2027 launch.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Taysha Gene Therapies Presents Promising TSHA-102 Data
- Taysha Gene Therapies presents new supplemental data analysis from REVEAL study
- Taysha Gene Therapies price target raised to $12 from $7 at Baird
- Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright
- Berkshire to acquire OxyChem, OpenAI reaches $500B valuation: Morning Buzz